EuroBiotech: More Articles of Note


> Nanobiotix created a subsidiary, Curadigm, to step up the use of nanoparticles to improve drug safety and bioavailability. Statement 

> Freeline posted preclinical data on its Fabry disease gene therapy. A single dose of the therapy sent GLA levels up to 1,061-fold higher than those of wild-type mice. Release 

> Transgene completed enrollment in a phase 2 trial that is testing TG4010 in combination with Opdivo. The milestone sets Transgene up to report primary endpoint data later this year. Statement  


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

> Mereo BioPharma posted six-month data from the open-label arm of a phase 2b trial in brittle bone disease. The data suggest setrusumab may improve bone density when Mereo reports data from the full study later this year. Statement 

> Orchard Therapeutics secured the worldwide license to an autologous hematopoietic stem cell gene therapy program for the treatment of Mucopolysaccharidosis Type I. Release  

> F-star completed the dose escalation phase of its FS118 study without seeing dose-limiting toxicities. Release 

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.